Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TRVI Stock Summary
In the News

Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham and Company Leland Gershell - Oppenheimer William Wood - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics' Second Quarter 2023 Earnings Conference Call.

Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Nat Charoensook - SVB Securities Sean Kim - Jones Trading Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call.

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.

Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics Q3 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.

Andreas Halvorsen Enters Holding in Trevi Therapeutics
Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global Investors LP, revealed in a Schedule 13G filing that he entered a new position in Trevi Therapeutics Inc. ( TRVI , Financial).

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Trevi Therapeutics to Present at Upcoming August Conferences
NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit (In-person) Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants.

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

How to Find Trending Penny Stocks in 2022
Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
TRVI Financial details
TRVI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.29 | -1.46 | -1.81 | -1.49 | -0.45 | |
Operating cash flow per share | -2.04 | -1.29 | -1.61 | -1.27 | -0.44 | |
Free cash flow per share | -2.06 | -1.3 | -1.61 | -1.27 | -0.44 | |
Cash per share | 1.91 | 3.21 | 2.49 | 1.61 | 1.87 | |
Book value per share | 1.93 | 3.06 | 1.51 | 0.75 | 1.66 | |
Tangible book value per share | 1.93 | 3.06 | 1.51 | 0.75 | 1.66 | |
Share holders equity per share | 1.93 | 3.06 | 1.51 | 0.75 | 1.66 | |
Interest debt per share | 0.02 | 0.02 | 0.81 | 0.69 | 0.15 | |
Market cap | 70.74M | 66.88M | 43.7M | 17.87M | 124.57M | |
Enterprise value | 53.57M | 9.92M | 12.91M | -4.33M | 121.15M | |
P/E ratio | -3.44 | -2.57 | -1.33 | -0.53 | -4.27 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.87 | -2.9 | -1.51 | -0.62 | -4.42 | |
PFCF ratio | -3.83 | -2.89 | -1.51 | -0.62 | -4.4 | |
P/B Ratio | 4.09 | 1.23 | 1.6 | 1.05 | 1.16 | |
PTB ratio | 4.09 | 1.23 | 1.6 | 1.05 | 1.16 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.62 | -0.37 | -0.4 | 0.13 | -4.05 | |
EV to operating cash flow | -2.93 | -0.43 | -0.45 | 0.15 | -4.3 | |
EV to free cash flow | -2.9 | -0.43 | -0.44 | 0.15 | -4.28 | |
Earnings yield | -0.29 | -0.39 | -0.75 | -1.9 | -0.23 | |
Free cash flow yield | -0.26 | -0.35 | -0.66 | -1.62 | -0.23 | |
Debt to equity | 0 | 0.01 | 0.52 | 0.86 | 0.09 | |
Debt to assets | 0 | 0.01 | 0.3 | 0.38 | 0.07 | |
Net debt to EBITDA | 0.84 | 2.14 | 0.95 | 0.68 | 0.11 | |
Current ratio | 7.02 | 11.45 | 8.33 | 2.98 | 9.15 | |
Interest coverage | -105.79 | 0 | -71.25 | -27.02 | -38.34 | |
Income quality | 0.89 | 0.89 | 0.89 | 0.85 | 0.97 | |
Dividend Yield | 0 | 0.03 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.09 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -6.87 | -0.23 | -0.68 | 0 | -3.7 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 9.98 | 10.03 | 7.85 | 5 | 4.11 | |
ROIC | -1.06 | -0.48 | -0.78 | -1.02 | -0.26 | |
Return on tangible assets | -1 | -0.43 | -0.7 | -0.88 | -0.24 | |
Graham Net | 1.65 | 2.98 | 1.43 | 0.68 | 1.63 | |
Working capital | 16.11M | 54.35M | 40.71M | 25.23M | 109.22M | |
Tangible asset value | 17.31M | 54.55M | 27.28M | 17.08M | 107.46M | |
Net current asset value | 15.61M | 54.1M | 26.42M | 16.56M | 107.06M | |
Invested capital | 0 | 0.01 | 0.52 | 0.86 | 0.09 | |
Average receivables | 122.5K | 371K | 411.5K | 253K | 120.5K | |
Average payables | 570K | 1.1M | 1.81M | 2.43M | 2.85M | |
Average inventory | 729.5K | 1.5M | 1.25M | 447.5K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.19 | -0.48 | -1.2 | -1.99 | -0.27 | |
Capex per share | -0.02 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.14 | -0.12 | -0.06 | -0.06 | -0.07 | |
Operating cash flow per share | -0.1 | -0.12 | -0.06 | -0.08 | -0.1 | |
Free cash flow per share | -0.1 | -0.12 | -0.07 | -0.08 | -0.1 | |
Cash per share | 1.31 | 1.82 | 1.23 | 1.13 | 0.95 | |
Book value per share | 1.02 | 1.6 | 1.1 | 1.03 | 0.96 | |
Tangible book value per share | 1.02 | 1.6 | 1.1 | 1.03 | 0.96 | |
Share holders equity per share | 1.02 | 1.6 | 1.1 | 1.03 | 0.96 | |
Interest debt per share | 0.21 | 0.16 | 0.1 | 0.09 | 0.02 | |
Market cap | 167.31M | 106.1M | 189.4M | 182.43M | 235.89M | |
Enterprise value | 155.14M | 50.39M | 185.99M | 179.79M | 223.61M | |
P/E ratio | -5.19 | -3.21 | -8.6 | -7.13 | -8.25 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -27.09 | -12.37 | -29.92 | -22.26 | -23.89 | |
PFCF ratio | -27.09 | -12.37 | -29.38 | -22.1 | -23.79 | |
P/B Ratio | 2.76 | 0.97 | 1.76 | 1.79 | 2.48 | |
PTB ratio | 2.76 | 0.97 | 1.76 | 1.79 | 2.48 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -20.09 | -6.25 | -27.94 | -23.77 | -31.99 | |
EV to operating cash flow | -25.12 | -5.88 | -29.38 | -21.93 | -22.64 | |
EV to free cash flow | -25.12 | -5.88 | -28.85 | -21.78 | -22.55 | |
Earnings yield | -0.05 | -0.08 | -0.03 | -0.04 | -0.03 | |
Free cash flow yield | -0.04 | -0.08 | -0.03 | -0.05 | -0.04 | |
Debt to equity | 0.21 | 0.1 | 0.09 | 0.09 | 0.02 | |
Debt to assets | 0.15 | 0.08 | 0.07 | 0.08 | 0.01 | |
Net debt to EBITDA | 1.58 | 6.91 | 0.51 | 0.35 | 1.76 | |
Current ratio | 5.18 | 8.7 | 9.15 | 8.65 | 21.06 | |
Interest coverage | -40.94 | -41.4 | -33.28 | -43.97 | -55.51 | |
Income quality | 0.77 | 1.04 | 1.15 | 1.28 | 1.38 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.02 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -7.73 | -3 | -1.18 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.76 | 2.08 | 1.18 | 1.23 | 1.25 | |
ROIC | -0.11 | -0.07 | -0.06 | -0.07 | -0.09 | |
Return on tangible assets | -0.1 | -0.06 | -0.04 | -0.06 | -0.07 | |
Graham Net | 0.96 | 1.56 | 1.07 | 0.98 | 0.89 | |
Working capital | 64.45M | 112.68M | 109.22M | 101M | 94.5M | |
Tangible asset value | 60.52M | 109.9M | 107.46M | 101.73M | 95.07M | |
Net current asset value | 58.99M | 108.86M | 107.06M | 99.73M | 93.31M | |
Invested capital | 0.21 | 0.1 | 0.09 | 0.09 | 0.02 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.84M | 3.14M | 2.6M | 2.42M | 1.67M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.08 | -0.05 | -0.06 | -0.08 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
TRVI Frequently Asked Questions
What is Trevi Therapeutics, Inc. stock symbol ?
Trevi Therapeutics, Inc. is a US stock , located in New haven of Ct and trading under the symbol TRVI
Is Trevi Therapeutics, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $12. The lowest prediction is $12 and the highest is $12
What is TRVI stock prediction ?
What is Trevi Therapeutics, Inc. stock quote today ?
Trevi Therapeutics, Inc. stock price is $2.275 today.
Is Trevi Therapeutics, Inc. stock public?
Yes, Trevi Therapeutics, Inc. is a publicly traded company.